November 23, 2016 - By Marguerite Chambers · 0 Comments
The stock of Acelrx Pharmaceuticals Incorporated (NASDAQ:ACRX) registered an increase of 0.24% in short interest. ACRX’s total short interest was 3.84 million shares in November as published by FINRA. Its up 0.24% from 3.83 million shares, reported previously. With 146,300 shares average volume, it will take short sellers 26 days to cover their ACRX’s short positions. The short interest to Acelrx Pharmaceuticals Incorporated’s float is 14.38%. About 679 shares traded hands. AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) has declined 15.32% since April 21, 2016 and is downtrending. It has underperformed by 20.65% the S&P500.
AcelRx Pharmaceuticals, Inc. is a pharmaceutical firm focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The company has a market cap of $142.80 million. The Firm operates through the segment, which includes development and commercialization of product candidates for the treatment of pain. It currently has negative earnings. The Company’s lead product candidates include ARX-04, Zalviso, which utilize sublingual sufentanil, delivered through a non-invasive route of administration, and ARX-03.
Insitutional Activity: The institutional sentiment increased to 1.22 in Q2 2016. Its up 0.28, from 0.94 in 2016Q1. The ratio increased, as 17 funds sold all AcelRx Pharmaceuticals Inc shares owned while 14 reduced positions. 15 funds bought stakes while 14 increased positions. They now own 16.10 million shares or 4.22% more from 15.45 million shares in 2016Q1.
Moreover, Blackrock Fund Advsr has 0% invested in AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) for 921,567 shares. Royal Commercial Bank Of Canada has 1,125 shares for 0% of their US portfolio. The Ontario – Canada-based Manufacturers Life Company The has invested 0% in AcelRx Pharmaceuticals Inc (NASDAQ:ACRX). California State Teachers Retirement Sys accumulated 74,215 shares or 0% of the stock. Palo Alto Invsts Ltd accumulated 0.29% or 1.43M shares. Northern Trust Corporation last reported 378,243 shares in the company. Savings Bank Of Mellon Corporation holds 0% of its portfolio in AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) for 145,477 shares. The New York-based Bnp Paribas Arbitrage has invested 0% in AcelRx Pharmaceuticals Inc (NASDAQ:ACRX). Moreover, Price T Rowe Assoc Md has 0% invested in AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) for 21,718 shares. Bridgeway Capital Incorporated owns 281,650 shares or 0.01% of their US portfolio. Renaissance Tech Limited Com last reported 21,100 shares in the company. Creative Planning has 0% invested in the company for 14,100 shares. Morgan Stanley accumulated 21,337 shares or 0% of the stock. Moreover, Joel Isaacson & Co Ltd Liability has 0.05% invested in AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) for 80,660 shares. Wealthtrust Axiom Ltd Company holds 0.13% or 130,000 shares in its portfolio.
Insider Transactions: Since September 15, 2016, the stock had 0 insider purchases, and 2 selling transactions for $2.30 million net activity. On Thursday, September 15 the insider PERCEPTIVE ADVISORS LLC sold $1.45M.
Out of 5 analysts covering AcelRx Pharmaceuticals (NASDAQ:ACRX), 5 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. AcelRx Pharmaceuticals has been the topic of 11 analyst reports since August 4, 2015 according to StockzIntelligence Inc. As per Friday, May 6, the company rating was upgraded by Seaport Global. The rating was maintained by TH Capital on Thursday, September 15 with “Buy”. TH Capital maintained AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) on Monday, October 5 with “Buy” rating. The rating was upgraded by Jefferies to “Buy” on Friday, October 30. The firm has “Hold” rating given on Tuesday, August 4 by Cowen & Co. On Monday, October 5 the stock rating was maintained by Roth Capital with “Buy”. The firm has “Buy” rating by H.C. Wainwright given on Tuesday, May 3. The company was initiated on Wednesday, September 2 by H.C. Wainwright.
AcelRx Pharmaceuticals, Inc., incorporated on July 13, 2005, is a specialty pharmaceutical firm focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Firm operates through the segment, which includes development and commercialization of product candidates for the treatment of pain. The Company’s lead product candidates include ARX-04 and Zalviso, which utilizes sublingual sufentanil, delivered through a non-invasive route of administration. The Company’s product candidate pipeline also includes ARX-03, which is a single, fixed-dose, combination drug product designed to provide mild sedation, anxiety reduction and pain relief for patients undergoing painful procedures in a physician’s office. It also includes ARX-02, which is meant for the treatment of patients who suffer from breakthrough pain (BTP) due to cancer.
More notable recent AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) news were published by: Prnewswire.com which released: “AcelRx Pharmaceuticals’ ARX-04 Phase 3 Trial Met its Primary Endpoint, Reduced …” on August 15, 2016, also Prnewswire.com with their article: “AcelRx Pharmaceuticals to Hold Third Quarter Financial Results Conference Call …” published on October 24, 2016, Thestreet.com published: “AcelRx Pharmaceuticals: What Went Wrong and What’s on the Horizon for the …” on March 23, 2015. More interesting news about AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) were released by: Prnewswire.com and their article: “AcelRx Pharmaceuticals Provides Corporate Update and Reports Second Quarter …” published on July 28, 2016 as well as Fool.com‘s news article titled: “Why AcelRx Pharmaceuticals Inc. Is Crashing” with publication date: March 10, 2015.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Marguerite Chambers